Use of fMRI and advanced analytics to develop and discover drugs for neuropsychiatric diseases.
Pain relief without the side effects
Arylepoxamides are novel compounds which binds to a newly discovered receptor, AEAr. The AEAr is widely distributed throughout the neuro-axis. In preclinical studies, arylepoxamides demonstrate potent analgesia and a clean safety profile lacking respiratory depression, physical dependence and reward behavior.
Preclinical IND-enabling tox ongoing
Phase 1 clinical anticipated in 2021
Attacking addiction head on
Mitragynine derives from the kratom plant. Dr. Majumdar has characterized its unique pharmacologic profile. It has attributes which make it a suitable candidate for opioid use disorder.
Discovery / Preclinical Development
Bringing personalized medicine to the brain
Sparian is collaborating with a spin out of the Brigham and Women's Hospital/Harvard Medical School which is pioneering the use of functional MRI (fMRI) technology and advanced analytics to better understand the neurobiology of disease and the response to treatment. We are looking to use this technology to enhance the precision and success of neuropsychiatric drug development.